CureVac AG. (2/26/20). "Press Release: CureVac Appoints Alan Kimura, MD, PhD as Head of the Newly Created Department “Rare Diseases”". Tübingen & Boston, MA.

	Organisation	CureVac AG
	Today	CureVac SE
	Group	CureVac (Group)
	Organisation 2	Enzyvant Therapeutics
	Group	Sumitomo (Group)
	Product	RNA-based therapeutic
	Product 2	DRUGS, ORPHAN
	Person	Kimura, Alan (CureVac 202002– Head of Rare Diseases before Enzyvant + SutroVax + Translate Bio + Shire + Novartis)
	Person 2	Menichella, Daniel L. (Dan) (Kaleido Biosciences 202010– CEO before CureVac + Bamboo Therapeutics + AGTC + Zyngenia)

CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, has appointed Alan Kimura MD, PhD as head of the newly created department “Rare Diseases”. Within this department, Curevac unites the therapeutic areas "Molecular Therapies" and "Eye and Lung". This reorganization will synergize and strengthen CureVac's activities across these therapeutic fields. In his new role, Dr. Kimura will report to Dr. Bernd Winterhalter, Interim Chief Development Officer (CDO) of CureVac.

"We are very excited to welcome Alan to CureVac. With him, we gained a highly competent and internationally experienced leader for our newly created therapeutic area Rare Diseases", says Daniel Menichella, Chief Executive Officer (CEO) of CureVac, "With his extensive expertise, he will provide important leadership and direction in the development of our mRNA-based product candidates for the treatment of rare diseases. In doing so, he will actively support our goal of saving patients’ lives with our unique mRNA platform technology."

"As a pioneer, CureVac has long been a leading company in developing and optimizing mRNA-based drugs and is now focused on discovering the potential of mRNA to treat a broad group of diseases. For me, it is a great honor to be a part of CureVac on its path towards the development and approval of mRNA-based products that will impact patients’ lives," says Alan Kimura.

Dr. Kimura has more than 30 years of experience in the pharmaceutical industry, including five years in research and more than 25 years in global clinical development. During this time, he was responsible for the clinical development of product candidates in phases 1 to 3, medical and regulatory affairs, as well as product lifecycle management.

Prior to joining CureVac, he served as Chief Medical Officer at Enzyvant and SutroVax, and Vice President, Clinical Development at Translate Bio. Dr. Kimura has also held senior clinical development, research, and medical affairs roles at Shire, Novartis, Altus, Transkaryotic Therapies, SmithKline Beecham, and Wyeth. He has authored more than 30 research papers and book chapters.

About CureVac AG

CureVac is a leading clinical stage biotechnology company in the field of messenger RNA (mRNA) technology with 20 years expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. CureVac has received significant investments, amongst others from dievini Hopp BioTech holding and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, Genmab, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, and others. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.

For more information, please visit www.curevac.com or follow us on Twitter at @CureVacAG.

***

Media Contact

Thorsten Schüller, Corporate Communications
CureVac AG, Tübingen, Germany
T: +49 7071 9883-1577
thorsten.schueller@curevac.com

Record changed: 2024-08-24